(±)-Stylopine

(±)-Stylopine (Tetrahydrocoptisine) is an alkaloid compound. (±)-Stylopine can be isolated from the tubers of the plant Corydalis. (±)-Stylopine inhibits TNF-α, IL-6, and NO production, and attenuates phosphorylation of p38 MAPK, ERK1/2. (±)-Stylopine inhibits NF-κB expression. (±)-Stylopine exhibits anti-inflammatory activity. (±)-Stylopine has protective effects against foot edema, gastric ulcers, anxiety, depression, and acute lung injury^[1][2][3][4]. In Vitro:(±)-Stylopine (10^-4 -1 μg/mL; 24 h pretreatment before 12 h LPS stimulation) significantly inhibits LPS-induced TNF-α, IL-6 production^[1].
In Vivo:(±)-Stylopine (7-21 mg/kg; i.p.; 30 min before modeling) inhibits Carrageenan (HY-125474)-induced rat paw edema and reduces TNF-α, IL-6 levels in paw tissue^[1].
(±)-Stylopine (10-20 mg/kg; i.p.; 3 days) attenuates ethanol-induced gastric ulcer in mice, reduces NO, TNF-α, IL-6 levels, MPO activity and NF-κB expression in gastric tissue and serum^[2].
(±)-Stylopine (18.4-36.8 mg/kg; i.p.; 14 days) alleviates LPS-induced neuroinflammation in mice, improves anxiety, depression and anhedonia, reduces neurodegeneration, inhibits KMO expression, NO and lipid peroxidation^[3].
(±)-Stylopine (10-20 mg/kg; i.p.; 30 min before LPS injection) reduces mortality, ameliorates lung injury, inhibits inflammatory cell infiltration, protein leakage, TNF-α, IL-6 production and NF-κB activation in LPS-induced acute lung injury in rats^[4].